|
|
 Previous Article | Table of Contents | Next Article 
Blood, 1 January 2001, Vol. 97, No. 1, pp. 107-113
GENE THERAPY
Systemic delivery of an adenoviral vector encoding canine factor
VIII results in short-term phenotypic correction, inhibitor
development, and biphasic liver toxicity in hemophilia A
dogs
Angela M. Gallo-Penn,
Pamela S. Shirley,
Julie L. Andrews,
Shawn Tinlin,
Sandy Webster,
Cherie Cameron,
Christine Hough,
Colleen Notley,
David Lillicrap,
Michael Kaleko, and
Sheila Connelly
From Queen's University, Kingston, Ontario, Canada,
and Genetic Therapy, Inc, a Novartis Company, Gaithersburg, MD.
Canine hemophilia A closely mimics the human disease and has been
used previously in the development of factor VIII (FVIII) protein
replacement products. FVIII-deficient dogs were studied to evaluate an
in vivo gene therapy approach using an E1/E2a/E3-deficient adenoviral
vector encoding canine FVIII. Results demonstrated a high level of
expression of the canine protein and complete phenotypic correction of
the coagulation defect in all 4 treated animals. However, FVIII
expression was short-term, lasting 5 to 10 days following vector
infusion. All 4 dogs displayed a biphasic liver toxicity, a transient
drop in platelets, and development of anticanine FVIII antibody. Canine
FVIII inhibitor development was transient in 2 of the 4 treated
animals. These data demonstrate that systemic delivery of attenuated
adenoviral vectors resulted in liver toxicity and hematologic changes.
Therefore, the development of further attenuated adenoviral vectors
encoding canine FVIII will be required to improve vector safety and
reduce the risk of immunologic sequelae, and may allow achievement of
sustained phenotypic correction of canine hemophilia A.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. Stone, Y. Liu, D. Shayakhmetov, Z.-Y. Li, S. Ni, and A. Lieber
Adenovirus-Platelet Interaction in Blood Causes Virus Sequestration to the Reticuloendothelial System of the Liver
J. Virol.,
May 1, 2007;
81(9):
4866 - 4871.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Al-Hendy and S. Salama
Gene therapy and uterine leiomyoma: a review
Hum. Reprod. Update,
July 1, 2006;
12(4):
385 - 400.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Jiang, D. Lillicrap, S. Patarroyo-White, T. Liu, X. Qian, C. D. Scallan, S. Powell, T. Keller, M. McMurray, A. Labelle, et al.
Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs
Blood,
July 1, 2006;
108(1):
107 - 115.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Kang, L. Xie, D. T. Tran, C. S. Stein, M. Hickey, B. L. Davidson, and P. B. McCray Jr
Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer
Blood,
September 1, 2005;
106(5):
1552 - 1558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. R. Arruda, H. H. Stedman, T. C. Nichols, M. E. Haskins, M. Nicholson, R. W. Herzog, L. B. Couto, and K. A. High
Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model
Blood,
May 1, 2005;
105(9):
3458 - 3464.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Xu, T. C. Nichols, R. Sarkar, S. McCorquodale, D. A. Bellinger, and K. P. Ponder
Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy
PNAS,
April 26, 2005;
102(17):
6080 - 6085.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Dobrzynski, F. Mingozzi, Y.-L. Liu, E. Bendo, O. Cao, L. Wang, and R. W. Herzog
Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer
Blood,
August 15, 2004;
104(4):
969 - 977.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Brown, C. X. Shi, S. Powell, D. Hurlbut, F. L. Graham, and D. Lillicrap
Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A
Blood,
February 1, 2004;
103(3):
804 - 810.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. Scallan, T. Liu, A. E. Parker, S. L. Patarroyo-White, H. Chen, H. Jiang, J. Vargas, D. Nagy, S. K. Powell, J. F. Wright, et al.
Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII
Blood,
December 1, 2003;
102(12):
3919 - 3926.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Ehrhardt, H. Xu, A. M. Dillow, D. A. Bellinger, T. C. Nichols, and M. A. Kay
A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia
Blood,
October 1, 2003;
102(7):
2403 - 2411.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. Scallan, D. Lillicrap, H. Jiang, X. Qian, S. L. Patarroyo-White, A. E. Parker, T. Liu, J. Vargas, D. Nagy, S. K. Powell, et al.
Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector
Blood,
September 15, 2003;
102(6):
2031 - 2037.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. K. L. Chuah, G. Schiedner, L. Thorrez, B. Brown, M. Johnston, V. Gillijns, S. Hertel, N. Van Rooijen, D. Lillicrap, D. Collen, et al.
Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors
Blood,
March 1, 2003;
101(5):
1734 - 1743.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. A. High
Gene Transfer as an Approach to Treating Hemophilia
Circ. Res.,
February 2, 2001;
88(2):
137 - 144.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
